International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1219-1227 , 15 March 2009

Inhibition of 4E-BP1 Sensitizes U87 Glioblastoma Xenograft Tumors to Irradiation by Decreasing Hypoxia Tolerance

  • Ludwig Dubois, M.Sc.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • ,
  • Michaël G. Magagnin, Ph.D.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • ,
  • Arjen H.G. Cleven, M.D.

      Affiliations

    • Department of Pathology, GROW–School for Oncology and Developmental Biology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Sherry A. Weppler, M.Sc.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • ,
  • Beat Grenacher, B.Sc.

      Affiliations

    • Institute of Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    • ,
  • Willy Landuyt, Ph.D.

      Affiliations

    • Department of Experimental Radiobiology and Oncology, University Hospital Leuven, Leuven, Belgium
    • ,
  • Natasja Lieuwes, B.Sc.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • ,
  • Philippe Lambin, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • ,
  • Thomas A. Gorr, Ph.D.

      Affiliations

    • Institute of Veterinary Physiology, Vetsuisse Faculty and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    • ,
  • Marianne Koritzinsky, Ph.D.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • Division of Signaling Biology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
    • Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
    • ,
  • Bradly G. Wouters, Ph.D.

      Affiliations

    • Department of Radiation Oncology (Maastro Laboratory), GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
    • Division of Signaling Biology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
    • Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
    • Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    • Selective Therapeutics Program, Ontario Institute for Cancer Research, Toronto, Canada
    • Corresponding Author InformationReprint requests to: Bradly G. Wouters, Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave, Office 10-116, Toronto, ON M5G 2M9, Canada. Tel: (416) 581-7840; Fax: (416) 581-7840

Received 11 August 2008 ,Revised 18 November 2008 ,Accepted 2 December 2008.

References 

  1. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–864
  2. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999;68:913–963
  3. Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature. 1994;371:762–767
  4. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433:477–480
  5. Thumma SC, Kratzke RA. Translational control: A target for cancer therapy. Cancer Lett. 2007;258:1–8
  6. Gingras AC, Kennedy SG, O'Leary MA, et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998;12:502–513
  7. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314–10319
  8. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189–3199
  9. Pickering BM, Willis AE. The implications of structured 5' untranslated regions on translation and disease. Semin Cell Dev Biol. 2005;16:39–47
  10. Graff JR, Zimmer SG. Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 2003;20:265–273
  11. Jacobson BA, Alter MD, Kratzke MG, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 2006;66:4256–4262
  12. Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:1801–1811
  13. Magagnin MG, van den Beucken T, Sergeant K, et al. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics. 2008;8:1019–1028
  14. Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med. 2001;7:1128–1132
  15. Braunstein S, Karpisheva K, Pola C, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28:501–512
  16. Bi M, Naczki C, Koritzinsky M, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005;24:3470–3481
  17. Koritzinsky M, Magagnin MG, van den Beucken T, et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 2006;25:1114–1125
  18. Liu L, Cash TP, Jones RG, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell. 2006;21:521–531
  19. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–553
  20. Chittock RS, Hawronskyj JM, Holah J, et al. Kinetic aspects of ATP amplification reactions. Anal Biochem. 1998;255:120–126
  21. Weppler SA, Krause M, Zyromska A, et al. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiother Oncol. 2007;82:96–104
  22. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res. 2000;60:5879–5886
  23. Papandreou I, Krishna C, Kaper F, et al. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 2005;65:3171–3178
  24. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337
  25. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21:3232–3237
  26. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12:860–868
  27. Sarkaria JN, Schwingler P, Schild SE, et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol. 2007;2:751–757
  28. Koritzinsky M, Rouschop KM, van den Beucken T, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol. 2007;83:353–361
  29. Downes CP, Bennett D, McConnachie G, et al. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans. 2001;29:846–851
  30. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921

 The first and second authors contributed equally to this work.

 Conflict of interest: none.

 Supplementary material for this article can be found at www.redjournal.org.

PII: S0360-3016(08)03809-1

doi: 10.1016/j.ijrobp.2008.12.003

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1219-1227 , 15 March 2009

Article Tools

* Image Usage & Resolution